Moderna surges 177% after a historic milestone for mRNA techModerna Inc.ACTIVTRADES:MRNA.USActivTradesIon Jauregui – Analyst at ActivTrades Moderna shares (NASDAQ: MRNA) posted their biggest gain in history, surging 177% in Wednesday’s session and closing at $174.38, after announcing positive Phase 3 results for its personalized cancer vaccine. The move represents a turning point both for the company and for messenger RNA (mRNA) technology, which is taking a decisive step beyond vaccines against infectious diseases. From the $85.50 highs recorded in July, Moderna had entered a strong correction that took the stock to below $65, with a Point of Control (POC) around $46.35, where a large part of the trading volume during the decline was concentrated. Yesterday’s session completely changed the technical picture. The stock opened with a huge bullish gap at $114.43, driven by the clinical announcement, and buying continued throughout the session until reaching an intraday high of $176.61, before closing slightly below at $174.38. The opening gap resulted in a virtually vertical breakout of all relevant resistance levels, accompanied by extraordinary volume and unprecedented volatility in the company. The catalyst was the success of intismeran autogene, the personalized vaccine developed together with Merck. The treatment, designed based on the specific mutations of each patient’s tumor, demonstrated in Phase 3 a statistically significant reduction in the risk of melanoma recurrence and spread when administered alongside Keytruda. Beyond the immediate impact on the share price, the market interprets these results as the first major commercial validation of the mRNA platform in oncology. If regulatory approval confirms these results, Moderna would move beyond relying primarily on its COVID-19 vaccine business and enter one of the biotechnology sector’s highest-growth-potential markets: personalized cancer treatments. From a technical perspective, the huge bullish gap makes the area between $114 and $120 the first short-term support zone, while the continuation of the move will depend on the stock’s ability to consolidate this new range following a historic one-session rally. ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance and forecasting are not a synonym of a reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk. Political risk is unpredictable. Central bank actions can vary. Platform tools do not guarantee success.